These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18472211)

  • 1. Editorial comment on: Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
    Novara G
    Eur Urol; 2009 Oct; 56(4):706-7. PubMed ID: 18472211
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
    Liu HT; Chancellor MB; Kuo HC
    Eur Urol; 2009 Oct; 56(4):700-6. PubMed ID: 18472208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Fowler CJ
    Eur Urol; 2009 Mar; 55(3):712. PubMed ID: 18814958
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Schurch B
    Eur Urol; 2009 Mar; 55(3):711-2. PubMed ID: 18814956
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Haferkamp A
    Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
    [No Abstract]   [Full Text] [Related]  

  • 6. The case for bladder botulinum toxin application.
    Kim DK; Thomas CA; Smith C; Chancellor MB
    Urol Clin North Am; 2006 Nov; 33(4):503-10, ix. PubMed ID: 17011386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
    Sahai A; Dowson C; Khan MS; Dasgupta P
    BJU Int; 2008 Feb; 101(4):515-6; author reply 516-7. PubMed ID: 18234066
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
    Wyndaele JJ
    Eur Urol; 2008 May; 53(5):1019-20. PubMed ID: 17950988
    [No Abstract]   [Full Text] [Related]  

  • 9. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial comment.
    Blok BF
    Urology; 2010 Mar; 75(3):558. PubMed ID: 20211368
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment on: Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
    Pickard R
    Eur Urol; 2008 Mar; 53(3):626. PubMed ID: 17950524
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Cartwright R; Cardozo L
    J Urol; 2007 Feb; 177(2):796-7; author reply 797. PubMed ID: 17222687
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.
    Haferkamp A; Schurch B; Reitz A; Krengel U; Grosse J; Kramer G; Schumacher S; Bastian PJ; Büttner R; Müller SC; Stöhrer M
    Eur Urol; 2004 Dec; 46(6):784-91. PubMed ID: 15548448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment on: Intraprostatic and bladder-neck botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
    Michel M
    Eur Urol; 2008 Mar; 53(3):626-7. PubMed ID: 17950523
    [No Abstract]   [Full Text] [Related]  

  • 15. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
    Kuo HC
    Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
    Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
    J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
    Kuo HC
    Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
    da Silva CM; Cruz F
    Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
    Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
    Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.